Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis.

Ann Surg Oncol · 2021 · PMC8184698 · PMID 33249520

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

approached significancep = 0.052so close (0.05 < p ≤ 0.1)

Pathologic Complete Response (ypT0N0) In total, 451 (23.2%) patients in the CROSS group had a total pCR (ypT0N0), compared with 277 (20.4%) in the e-CROSS group, which approached significance ( p = 0.052) (Table 2 ).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.